蛋白质与RNA在早期胰腺癌诊断中的研究进展

Progress of protein and RNA in the diagnosis of early pancreatic cancer

胰腺癌约90％起源于腺管上皮的导管腺癌，其最佳的治疗方法是早期手术切除。由于胰腺癌早期缺乏特异性临床症状，多数患者确诊后已进入晚期阶段，肿瘤已发生远处转移而无法施行根治性手术．且胰腺癌对放、化疗均不敏感，所以只能选择姑息治疗。蛋白质与RNA可在组织、排泄物、血清、血浆及稳定地提取和检测，能有效降低成本和技术难度。随着蛋白质组学以及RNA组学技术的发展，越来越多的新的肿瘤标志物被发现，这些新的肿瘤标志物在一定程度上能有利于提高胰腺癌早期确诊率，从而提高胰腺癌患者的肿瘤根治性手术切除率，改善患者预后。本文将从蛋白质及RNA水平的研究介绍近几年的胰腺癌的生物标志物。

About 90% of pancreatic cancers originate from ductal adenocarcinoma of the ductal epithelium. The best treatment for this disease is surgical resection after early diagnosis. Due to lack of specific clinical symptoms in the early stage, most patients have entered the advanced stage after diagnosis, the tumor has undergone distant metastasis and can not perform radical surgery, and pancreatic cancer is not sensitive to radiotherapy and chemotherapy, so only palliative care can be chosen. Protein and RNA can be extracted and detected stably in tissues, excreta, serum, plasma, and can effectively reduce cost and technical difficulty. With the development of proteomics and RNAomics technology, more and more new tumor markers have been found. These new tumor markers can help to improve the early diagnosis rate of pancreatic cancer to a certain extent, thereby improving the radical surgery of pancreatic cancer patients. Resection rate improves patient prognosis. This article describes the biomarkers of pancreatic cancer in recent years from the study of protein and RNA levels.